Literature DB >> 10088766

Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis.

Y Asanuma1, S Kawai, H Aoshima, J Kaburaki, Y Mizushima.   

Abstract

OBJECTIVE: To determine serum lipoprotein(a) (Lp[a]) concentrations and to analyze the apolipoprotein(a) (Apo[a]) phenotype in patients with rheumatoid arthritis (RA).
METHODS: The subjects included 131 patients with RA and 200 healthy control subjects. Serum Lp(a) concentrations were measured by enzyme-linked immunosorbent assay, and the Apo(a) phenotype was determined by immunoblotting. HLA-DR typing was also done.
RESULTS: The mean serum Lp(a) level was significantly higher (P < 0.001) in the RA patients (27.5 mg/dl) than in the controls (15.0 mg/dl). The S3 allele was found in 70.0% of the patients versus 39.5% of the controls (P < 0.001). There was no significant difference in HLA-DR4 positivity between patients with and without the S3 phenotype.
CONCLUSION: The serum Lp(a) level was increased in patients with RA, possibly partly because of S3 phenotype predominance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088766     DOI: 10.1002/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO;2-Q

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

1.  Ethnicity may be a reason for lipid changes and high Lp(a) levels in rheumatoid arthritis.

Authors:  Mustafa Cesur; Zeynep Ozbalkan; Mehtap Akcil Temel; Yaşar Karaarslan
Journal:  Clin Rheumatol       Date:  2006-05-06       Impact factor: 2.980

2.  Increased hospitalizations and death in patients with ESRD secondary to lupus.

Authors:  S Sule; B Fivush; A Neu; S Furth
Journal:  Lupus       Date:  2012-06-26       Impact factor: 2.911

3.  Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis.

Authors:  Jasmina Ivaniševic; Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Jelena Kotur-Stevuljevic; Vesna Spasojevic-Kalimanovska; Slavica Spasic; Violeta Vucinic-Mihailovic; Jelica Videnovic-Ivanov; Zorana Jelic-Ivanovic
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 4.  Lipoprotein (a) and stroke.

Authors:  H J Milionis; A F Winder; D P Mikhailidis
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

5.  Cardiovascular Complications of Collagen Vascular Disease.

Authors:  Gary E. Sander; Thomas D. Giles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-04

6.  IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans.

Authors:  Nike Müller; Dominik M Schulte; Kathrin Türk; Sandra Freitag-Wolf; Jochen Hampe; Rainald Zeuner; Johann O Schröder; Ioanna Gouni-Berthold; Heiner K Berthold; Wilhelm Krone; Stefan Rose-John; Stefan Schreiber; Matthias Laudes
Journal:  J Lipid Res       Date:  2015-02-21       Impact factor: 5.922

Review 7.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

8.  Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.

Authors:  Cecilia P Chung; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; Ingrid Avalos; Tuulikki Sokka; Paolo Raggi; Theodore Pincus; C Michael Stein
Journal:  Arthritis Rheum       Date:  2008-07

Review 9.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Saurabh S Dhawan; Arshed A Quyyumi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

Review 10.  Atherosclerotic cardiovascular disease in rheumatoid arthritis.

Authors:  Inmaculada del Rincón; Agustín Escalante
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.